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Abstract Purpose: We studied
gene expression differences in brain
homogenate, hippocampus, somato-
sensory cortex and cerebellum of rats
suffering from sepsis-associated
delirium and analyzed the effects of
norepinephrine and 1,400 W (specific
inhibitor of the inducible nitric-oxide
synthase). Methods: We applied
microarray screenings to rat brain
homogenate 1, 3 and 4.5 h after
lipopolysaccharide (LPS, 5 mg/kg) or
0.9% NaCl treatment. Therapy groups
were analyzed after 4.5 h. Validations
and compartment specific investiga-
tions were carried out by real-time
PCR. Results: Most striking gene
expression differences were seen
4.5 h after LPS administration, espe-
cially within the hippocampus
(chemokines and endothelial cell-
specific molecule 1). Norepinephrine
resulted in a discrete chemokine up-
regulation, while 1,400 W had hardly
any effect. Conclusion: Strongest
gene regulations were found within
the hippocampus. Norepinephrine
showed a tendency of having a pro-
inflammatory influence, while
1,400 W had no clear-cut effect onto
the gene expression level.
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Introduction
Sepsis-associated delirium (Diagnostic and statistical
Manual, DSM IV; International Classification of Diseases,
ICD 10) is a severe global cerebral dysfunction [1]. It is
present in up to 70% and is associated with an increase in
mortality due to sepsis [1, 2]. An unspecific psychosyn-
drome with alterations of consciousness is the main
clinicalblank;symptom. In most of the cases its clinical
appearance precedes other symptoms of general inflam-
mation [2–4]. Perimicrovascular edema and bleeding,
endothelial activation, neuronal apoptosis, glial activation,
ion channel differences, synthesis of the inducible nitric-
oxide synthase (iNOS) and changes in neurotransmitter
release or concentrations have been reported [1–3, 5, 6].
Nevertheless, its pathophysiology is poorly understood
andblank;little is known about gene expression differences
within the brain and its compartments during sepsis-related
encephalopathy.
In recent years the concept of early microcirculatory
dysfunction as a motor of sepsis-related organ failure
gained some attraction. Interestingly, microcirculatory
dysfunction and inappropriate blood supply of organ cells
on a microscopic level occur when overall blood flow and
blood pressure (BP) are still in the normal range. This
might explain, why studies on the overall cerebral blood
flow did not find a relation to early sepsis-associated
delirium [7, 8]. However, by preventing excessive NO-
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production selective iNOS inhibitors attenuate the vascu-
lar dysfunction in a sepsis syndrome such as hypotension,
endothelial dysfunction and microvascular shunting [9,
10]. They may additionally have immunomodulatory
properties which might improve outcome [11].
In this study we aimed to find candidate genes asso-
ciated with sepsis-associated delirium. As gene
expression alterations occur early in the course of sepsis
we required a standardized method concerning time and
severity and chose again an endotoxic shock model. We
analyzed gene expression differences of rat brain
homogenate on microarrays at the time points of pri-
marily recognized changes in the microvascular (1 h) and
neuronal dysfunction (3 h) and finally 4.5 h after LPS
administration before BP reached the critical lower level
of cerebral autoregulation [12]. For validation a subset of
genes was confirmed by real-time PCR. Additionally
some candidate genes were studied in different brain
compartments which are associated with clinical altera-
tions in sepsis-related encephalopathy (hippocampus,
somatosensory cortex, cerebellum).
To address the effect of selective iNOS inhibition in
more detail we investigated the genetic effects of 1,400 W
(N-[3-(aminomethyl)benzyl]acetamide) in the septic brain.
Norepinephrine prevents the hemodynamic break-
down during sepsis and belongs to the classic therapeutic
strategies. We studied whether rats being treated with
LPS and norepinephrine showed mRNA expression dif-
ferences within genes of interest found in the microarray
studies.
Materials and methods
Rat model of sepsis
All procedures performed on the animals were in strict
accordance with the National Institutes of Health Guide
for Care and Use of Laboratory Animals and approved by
the local Animal Care and Use Committee. The study was
approved by the Institutional Review Board for the care
of animal subjects.
Sprague Dawley rats (290–320 g) were initially anes-
thetized with isoflurane, tracheotomized, paralyzed with
pancuronium bromide [0.2 mg/(kg h)] and artificially
ventilated (Harvard Rodent Ventilator; Harvard, South
Natick, MA, USA). The right femoral artery and vein were
cannulated for BP recording, blood sampling and drug
administration. Rectal body temperature was maintained
at 37C using a feedback-controlled heating pad.
Approximately 60 min before LPS/placebo adminis-
tration, isoflurane anesthesia was discontinued and
replaced by an intravenous application of a-chloralose
(80 mg/kg; Sigma-Aldrich Chemie GmbH, Taufkirchen,
Germany). Supplementary doses of chloralose (30 mg/kg)
were given every hour. During chloralose anesthesia, the
animals were ventilated with a 1:1 mixture of nitrogen
and oxygen. Arterial blood gas analyses and pH were
measured repeatedly as needed and at least every 30 min
(Blood gas analyzer model Rapidlab 348, Bayer Vital
GmbH, Fernwald, Germany). Also glucose and lactate
levels were measured repeatedly (Glukometer Elite XL,
Bayer Vital GmbH, Fernwald, Germany; Lactate pro,
Arkray Inc. European Office, Du¨sseldorf, Germany).
Glucose levels were kept at [60 mg/dl.
In random order 54 rats intravenously received 5 mg/
kg body weight LPS (from Escherichia coli, O111:B4,
Sigma-Aldrich Chemie GmbH, Germany) or 0.5 ml of
0.9% NaCl. LPS was solved in 0.5 ml of 0.9% NaCl and
slowly given within 5 min. A moderate volume therapy of
1.2 ml/h of 0.9% NaCl was given to replace renal and
perspirative fluid losses. Septic rats and sham controls
were killed 1, 3 or 4.5 h after LPS or NaCl administration.
Each experimental group consisted of nine animals.
Additionally, 18 rats received norepinephrine
(Aventis GmbH, Bad Soden, Germany) or 1,400 W
(Alexis Corporation, San Diego, USA) intravenously,
beginning 1 h after LPS infusion. About 1,400 W was
primarily applied as a bolus (2.6 mg/kg), followed by a
continuous infusion (2.6 mg/kg 9 h). This dose was
known to improve mean systemic arterial blood pressure
(SAP) in the range of 80–90 mmHg. To achieve resto-
ration of SAP accordingly continuous infusion of
norepinephrine was titrated (0.01–10 lg/kg 9 min).
Brains were removed and stored at -80C.
RNA isolation
Cryosections (10 lm) of whole rat brain or brain com-
partments were mixed with 1 ml TriFast (PeqGOLD,
peqlab, Erlangen, Germany) and homogenized using a
20 G needle. After addition of 200 ll chloroform (Sigma-
Aldrich, Steinhelm, Germany), mixing, 10 min incuba-
tion at 4C and centrifugation (4C, 20,000g, 15 min), the
upper phase was transferred into a new vial. After addi-
tion the same volume of 70% ethanol, RNA was isolated
using the RNeasy Mini Kit (Qiagen, Hilden, Germany)
following the manufacturer’s instructions including a
DNase digestion (RNase-free DNase Set, Qiagen). RNA
was eluted in 34 ll of RNase-free water, and quality was
assessed by capillary electrophoresis using the Bioana-
lyzer 2100 (Agilent Technologies, Palo Alto, CA).
Microarray experiments
For labeling reactions 1 lg of pooled total RNA (n = 3
animals/pool) was used. Sample preparation (reverse tran-
scription, T7-RNA amplification, labeling, purification,
hybridization, washing and drying of the slides) was
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performed according to the Two-Color Microarray-Based
Gene Expression Analysis Protocol (Version 5.5) using the
RNA Spike-In Kit, the Low RNA Input Linear Amp Kit and
the Cyanine CTP2-color dye pack (Agilent Technologies,
Wilmington, USA).
Samples were alternatingly labeled using either Cy3 or
Cy5 to match a balanced dye-swap design. Labeled
aRNAs were hybridized overnight to 60mer oligonu-
cleotide-spotted microarray slides (Rat Whole Genome
4 9 44 K; Agilent Technologies).
The dried slides were scanned using a GenePix 4100A
scanner (Axon Instruments, Downingtown, PA). Image
analysis was performed using the GenePix Pro 5.0 soft-
ware, and calculated values for all spots were saved as
GenePix result files. Stored data were evaluated using the
R software and the limma package from BioConductor
[13–15]. The spots were weighted for subsequent analyses
according to the spot intensity, homogeneity and satura-
tion. Spot intensities were corrected for the local
background using the method of Edwards [16] with an
offset of 64 to stabilize the variance of low-intensity
spots. The M/A data were LOESS-normalized [17] before
averaging. Genes were ranked for differential expression
using a moderated t-statistic [18]. P values were adjusted
for multiple testing using the procedure of Benjamini and
Hochberg [19]. Candidate lists were created by adjusting
the false-discovery rate to 10%. Afterwards, some of the
genes found to be regulated were checked for their dif-
ferential expression in the whole time course. We
compared gene expression differences of following
groups: rats killed 1, 3 and 4.5 h after LPS versus NaCl
application and 4.5 h after LPS versus LPS ? 1,400 W (3
repetitions each).
Real-time PCR
To confirm the results obtained by microarray experi-
ments, the regulation of a subset of genes was analyzed by
real-time PCR using the DDCT method for the calculation
of relative changes [20]. Means and confidence intervals
were calculated from the DDCT data. P values were cal-
culated using a two-sided t-test.
Within some genes of interest we also analyzed
expression profiles in selected compartments. Differences
of the fold-expressions between the compartments
(Fig. 2) were analyzed by ANOVA and Dunnett’s mul-
tiple-to-one comparisons against homogenate (when
P \ 0.05). The logarithms of the fold-expressions were
used to obtain normal distributed residuals. Normal dis-
tribution was confirmed with Shapiro–Wilk test,
homogeneity of variances between groups was confirmed
with Levene’s test.
Per reaction, we used 1 lg of a total RNA. Real-time
PCR was performed using the 7900HT Fast Real-Time
PCR system (Applied Biosystems, Foster City, USA).
Porphobilinogen deaminase (PBGD) was used as refer-
ence gene. For cDNA synthesis, reagents and incubation
steps were applied as described previously [21]. PCR
reactions were set up using the Platinum SYBR Green
qPCR SuperMix-UDG (Invitrogen, Karlsruhe, Germany).
Sequences of the oligonucleotide primer pairs are given in
Table 1 (final concentration 200 nM). Cycling conditions
were 95C for 6 min, followed by 45 cycles of 95C for
5 s, 59C for 5 s and 72C for 15 s. For every gene we
performed three independent experiments comparing
pools of three animals each (performing double mea-
surements). Due to the non-selective dsDNA binding of




Primer sequence (50?30) Amplicon
length
(bp)Forward primer Reverse primer
Porphobilinogen deaminase
(PBGD)
25709 CAAGGTTTTCAGCATCGCTACCA ATGTCCGGTAACGGCGGC 135
Baculoviral IAP repeat-containing 3
(Birc3)
78971 TGGTCAGCAAAGTTCCGTAGG AGGAAGCAGCCTTTCTCC 119
Chemokine (C–C motif) ligand 2
(Ccl2)
24770 CATCCACGTGCTGTCTCAGC TCTCCAGCCGACTCATTGG 95
Chemokine (C–C motif) ligand 20
(Ccl20)
29538 TTCCTGGAGCTGAGAATGGC GTGTACGTGAGGCAGCAGTCA 122
Chemokine (C-X-C motif) ligand 1
(Cxcl1)
81503 GCCCCCATGGTTCAGAAGA GAAGCCAGCGTTCACCAGA 108
Chemokine (C-X-C motif) ligand 2
(Cxcl2)
114105 CCTTGGTTCAGAGGATCGTCC GATTCTGCCCGTTGAGGTACA 99
Chemokine (C-X-C motif) ligand 10
(Cxcl10)
245920 GTCGTTCTCTGCCTCGTGCT AGTTTTCCTATGGCCCTGGG 125
Endothelial cell-specific molecule 1
(Esm1)
64536 CATATGTGACAGGGTGACCGG TCTCACAGCATTGCCATCTCC 133
Lipocalin 2 (Lcn2) 170496 ACAACGTCACTTCCATCCTCG CCTGGAGCTTGGAACGAATG 74
Reelin (Reln) 24718 AAAGGCCAGCACCCGTTAC GCCCGAGATCCACGGAGTA 140
Sequences were taken from Gene bank, accession numbers are given
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the SYBR Green I dye, melting curve analysis and gel
electrophoresis were performed.
Western blot
We performed SDS-PAGE with 15% polyacrylamide gels
(stacking gel 5%) using the BioRad tank blot system
(BioRad, Munich, Germany). After incubation with Lae-
mmli buffer (5 min/95C), running the gel, blotting and
2 h of blocking (5% fat-free, skimmed milk/PBS), pri-
mary antibodies (detecting Cxcl1 and Cxcl2, US
Biological, Swampscott, MA, USA) were incubated
overnight (rotating 4C) and secondary antibodies
(labeled with horseradish peroxidase) for 1 h (room
temperature, moving). For detection of bands we used the
Amersham ECL Plus Western Blotting Detection
Reagents (GE Healthcare, Munich, Germany).
Immunofluorescence staining
Paraffin sections (10 lm) of septic brain were deparaffi-
nized and rehydrated using xylol and a series of ethanol in
PBS dilutions. Antigen retrieval was performed in a
microwave (630 W/7 min) with PBS/1 mM EDTA.
After cooling to room temperature, sections were
blocked with 5% BSA in PBS. Primary (1:100) and sec-
ondary antibodies (1:1,000, both in PBS/0.1% BSA) were
hybridized for 1 h at room temperature. After each
binding step, we washed with PBS/0.1% BSA. Nuclei
were stained with DAPI (1 lmol/ml, 5 min; AppliChem,
Darmstadt, Germany). Final fixation was performed with
4% paraformaldehyde (10 min).
Results
No rat died from LPS injection. As expected, rats
developed a severe sepsis syndrome with significant
drop in BP (Fig. 1) and pH and increase in lactate levels
(Table 2). The higher pH during baseline was related to
chloralose narcosis leading to metabolic alcalose [22].
pH decreased approximately by 0.1 in all groups till end
of experiments. According to a transient hypercapnia in
the norepinephrine group pH-levels were lower at 1 and
3 h. 1,400 W and norepinephrine stabilized BP in the
lower normal range (Fig. 1). Only norephinephrine
resulted in a lower lactate level at the end of experi-
ments (Table 2).
Fig. 1 Influence of norepinephrine and 1,400 W onto the mean
systemic arterial blood pressure (SAP) after LPS application.
Mean ± SEM of nine independent experiments each;
****P \ 0.0001 versus LPS/saline-treated animals. SAP was
significantly increased in both therapy groups
Table 2 Arterial blood gases
and lactate in rats with LPS-
induced septic shock in
response to norepinephrine and
1,400 W
Time after LPS (min) 0 60 180 270
PO2
LPS 265.8 ± 5.8 263.7 ± 4.5 273.9 ± 2.7 269.5 ± 4.6
LPS ? norepinephrine 279.6 ± 5.8 265.8 ± 6.1 263.1 ± 5.1 267.7 ± 4.9
LPS ? 1,400 W 264.0 ± 10.1 264.6 ± 9.6 259.8 ± 9.7 253.3 ± 17.3
PCO2
LPS 31.3 ± 1.0 34.7 ± 0.8 33.5 ± 0.7 32.3 ± 0.6
LPS ? norepinephrine 30.2 ± 0.5 39.8 ± 1.6*** 39.3 ± 1.2*** 32.8 ± 0.8
LPS ? 1,400 W 31.3 ± 0.5 33.2 ± 1.5 34.6 ± 2.3 32.6 ± 0.9
pH
LPS 7.56 ± 0.01 7.43 ± 0.01 7.45 ± 0.01 7.45 ± 0.01
LPS ? norepinephrine 7.57 ± 0.01 7.40 ± 0.02** 7.38 ± 0.02** 7.46 ± 0.02
LPS ? 1,400 W 7.57 ± 0.01 7.43 ± 0.02 7.42 ± 0.02 7.45 ± 0.01
Lactate
LPS 0.94 ± 0.17 2.57 ± 0.23 2.26 ± 0.10 2.37 ± 0.23
LPS ? norepinephrine 0.85 ± 0.20 2.18 ± 0.13 2.09 ± 0.20 1.53 ± 0.20**
LPS ? 1,400 W 0.82 ± 0.16 2.40 ± 0.17 2.34 ± 0.13 2.14 ± 0.07
PO2, PCO2 and pH: whole arterial blood data (A. femoralis); lactate: arterial plasma data; n = 9;
mean ± SEM
** P B 0.01, *** P B 0.001, rest: not significant
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Tables 3 and 4 show the group-averaged data of sev-
eral candidate genes found in microarray studies. The
most impressive regulations were observed in the group
of chemokines and interleukines. Other genes were
involved in coagulation, regulation of apoptosis, compo-
sition of extracellular matrix, metabolism, transcription
and cell cycle regulation.
The 1,400 W therapy group showed hardly any gene
expression differences compared to the intravenous LPS
group after 4.5 h (Table 4, complete list given).
Within the group of PCR-validated genes 100% were
confirmed to be up- or down-regulated (Table 5). In the
norepinephrine therapy group, real-time PCRs revealed a
tendency of chemokine-induction compared to the LPS
group (Table 5).
We additionally evaluated the expression level of
several LPS-induced genes within the hippocampus, the
somatosensory cortex and the cerebellum; Ccl2, Ccl20,
Cxcl2 and endothelial cell-specific molecule 1 (Esm1)
were found to be most intensively induced within the
hippocampus. The other compartments also frequently
showed a stronger gene regulation compared to brain
homogenate, yet to a lower degree (Fig. 2).
Studying Cxcl1 and Cxcl2 expression in brain
homogenate, we could confirm our RNA data on protein
level. Western blots revealed an increased expression of
Table 3 Gene expression differences 1, 3 and 4.5 h after intravenous LPS administration (microarray data)
Group Gene Ratio LPS/NaCl: mean ± SEM
Gene bank
accession
1 h 3 h 4.5 h
Inflammation Interleukin 1 beta (Il1b) NM_031512 4.04 ± 0.37* 6.66 ± 0.33*** 9.23 – 0.34***
Interleukin 6 (Il6) NM_012589 1.26 ± 0.33 NS 6.04 ± 0.30*** 6.65 – 0.30***
Chemokine (C-X-C motif) ligand 1
(Cxcl1)
NM_030845 5.53 ± 0.53 NS 11.92 ± 0.48*** 34.42 – 0.48***
Chemokine (C-X-C motif) ligand 2
(Cxcl2)
NM_053647 5.22 ± 0.40* 15.52 ± 0.37*** 33.43 – 0.37***
Chemokine (C-X-C motif) ligand 9
(Cxcl9)
NM_145672 0.86 ± 0.40 NS 3.01 ± 0.361* 4.26 – 0.37***
Chemokine (C-X-C motif) ligand 10
(Cxcl10)
NM_139089 1.36 ± 0.45 NS 15.74 ± 0.41*** 21.26 – 0.41***
Chemokine (C–C motif) ligand 2 (Ccl2) NM_031530 1.94 ± 0.44 NS 26.76 – 0.40*** 21.71 ± 0.41***
Chemokine (C–C motif) ligand 3 (Ccl3) NM_013025 2.15 ± 0.41 NS 3.65 ± 0.371** 4.45 – 0.38***
Chemokine (C–C motif) ligand 7 (Ccl7) NM_001007612 1.22 ± 0.278 NS 3.45 ± 0.252*** 4.39 – 0.26***
Chemokine (C–C motif) ligand 20 (Ccl20) NM_019233 0.99 ± 0.37 NS 8.73 ± 0.34*** 9.80 – 0.343***
Interferon stimulated exonuclease 20
(Isg20)
NM_001008510 1.10 ± 0.41 NS 4.39 – 0.37** 2.69 ± 0.37 NS
Interferon-induced protein with
tetratricopeptide repeats 2 (Ifit2)
NM_001024753 0.97 ± 0.38 NS 4.05 ± 0.34*** 4.18 – 0.35***
Similar to interferon-inducible GTPase
(MGC108823)
NM_001012353 0.97 ± 0.36 NS 5.20 – 0.33*** 3.17 ± 0.33**
Interferon-induced protein 44 (Ifi44) XM_227821 1.27 ± 0.32 NS 2.76 – 0.29** 2.52 ± 0.29*
Interferon gamma induced GTPase (Igtp) XM_220451 1.02 ± 0.23 NS 2.37 – 0.21*** 1.48 ± 0.21 NS
Tumor necrosis factor receptor
superfamily, member 5 (Tnfrsf5)
NM_134360 1.15 ± 0.28 NS 2.40 ± 0.25** 3.37 – 0.25***
Coagulation Protein C receptor, endothelial (Procr) NM_001025733 1.13 ± 0.30 NS 2.90 ± 0.28** 3.89 – 0.28***
Tissue factor pathway inhibitor 2 (Tfpi2) NM_173141 1.10 ± 0.39 NS 3.29 ± 0.36* 7.45 – 0.36***
Matrix
remodeling
Tissue inhibitor of metalloproteinase 1
(Timp1)
NM_053819 0.95 ± 0.43 NS 3.33 ± 0.39* 6.66 – 0.39***
Hyaluronan synthase 1 (Has1) NM_172323 1.21 ± 0.34 NS 4.41 ± 0.31*** 5.18 – 0.32***
Anti-apoptotic Baculoviral IAP repeat-containing 3
(Birc3)
NM_023987 1.24 ± 0.28 NS 2.65 ± 0.26** 4.72 – 0.26***
Endothelium Endothelial cell-specific molecule 1
(Esm1)
NM_022604 2.30 ± 0.50 NS 3.40 ± 0.45 NS 6.21 – 0.46***
Bacteriostatic Lipocalin 2 (Lcn2) NM_130741 1.06 ± 0.37 NS 1.92 ± 0.34 NS 3.15 – 0.34*
Kinase regulation Mitogen-activated protein kinase
kinase kinase 8 (Map3k8)
NM_053847 1.43 ± 043 NS 4.73 – 0.39** 2.91 ± 0.39 NS
Cell cycle
regulation
Splicing factor, arginine/serine-rich 5
(Sfrs5)
NM_019257 0.33 – 0.30* 0.56 ± 0.27 NS 1.21 ± 0.28 NS
The strongest regulations in the time course are given in bold let-
ters. In most of the cases they were found after 4.5 h. Expectedly,
the group of inflammation-associated genes was the largest and
contained the strongest gene regulations
NS not significant
* Adjusted P B 0.05; **adjusted P B 0.01, ***adjusted P B 0.001
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both molecules in the LPS-stimulated group (Fig. 3). In
the hippocampal area we found a neuron-specific staining
for Cxcl1 (positive reaction of the same cells with NeuN
antibody, which specifically marks neurons). Additionally
Cxcl2 was detected in axons of the white matter (Fig. 4).
Discussion
Early occurrence of gene expression alterations, induction
of cytokine levels together with neuronal dysfunction
point to a complex brain inflammatory response syndrome
(BIRS), which precedes the sepsis-induced systemic
response syndrome (SIRS). This concept is in line with
the clinical observation of early sepsis-associated delir-
ium as an indicator of a systemic sepsis syndrome [1–4].
Whereas modern therapeutic regimes mainly focus on the
prevention from early microcirculatory dysfunction the
immunomodulatory effects of iNOS inhibitors or cate-
cholamines in the septic brain were still unknown.
Microarray data revealed a strong chemokine up-reg-
ulation after 1 h, further increasing 3–4.5 h after
intravenous LPS injection (Table 3). Results were con-
firmed by real-time PCR; we actually found a more
pronounced regulation level using this method (Table 5),
what is a common phenomenon as the dynamic range of
microarrays is smaller than that of real-time PCR. This
becomes obvious especially when studying strongly reg-
ulated genes. Additionally, preamplification methods tend
to cause a data compression [23–25].
Cxcl1 and Cxcl2 were also proven to be up-regulated
in the LPS group on protein level (Fig. 3), yet to a lower
degree. Presumably, this discrepancy was caused by a
delayed induction of gene expression on the protein
level.
Chemokines play an important role in the recruitment
and regulation of leukocyte traffic during bacterial infec-
tion [26]. The Ccl2 (macrophage chemoattractant protein-
1, MCP-1) serum level in acute peritonitis was greatest in
patients who died [27]. Consistently, patients with severe
forms of sepsis revealed highest Ccl2 plasma levels [28].
Low Ccl2 plasma levels are associated with survival in
invasive pneumococcal disease and correlate with bacterial
loads in blood and cerebrospinal fluid, disease presentation
and outcome [26]. Intrahippocampal injections of Ccl2
or Cxcl2 (macrophage inflammatory protein-2, MIP-2)
resulted in the apoptosis of hippocampal neurons, thus
supporting a direct role of these chemokines in neuronal
death [29]. Yet chemokine-activated astrocytes seemed to
Table 4 Gene expression differences 4.5 h after intravenous LPS administration, 1,400 W therapy group (microarray data)
Gene Gene bank
accession
1,400 W ? LPS/LPS:
mean ± SEM
Inositol polyphosphate-4-phosphatase, type II (Inpp4b) NM_053917 2.37 ± 1.46 NS
NADH dehydrogenase (ubiquinone) 1, subcomplex unknown, 2 (Ndufc2) NM_001009290 2.09 ± 0.41 NS
Splicing factor, arginine/serine-rich 5 (Sfrs5) NM_019257 0.49 ± 0.28 NS
Olfactomedin 3 (Olfm3) NM_145777 0.45 ± 0.41 NS
Reelin (Reln) NM_080394 0.38 ± 0.51 NS
Synaptic vesicle glycoprotein 2b (Sv2b) NM_057207 0.21 ± 0.36**
NS not significant
** Adjusted P B 0.01. Except for Sv2b, we found no significant gene expression differences in the 1,400 W therapy group compared to
the LPS group











Ccl2 21.71 ± 0.41 40.53 (14.74:111.43)** 0.77 (0.35:1.69) NS 1.97 (0.29:13.34) NS
Ccl20 9.80 ± 0.34 167.09 (63.58:439.11)** 1.64 (0.45:6.00) NS 2.58 (0.08:81.08) NS
Cxcl1 34.42 ± 0.48 256.51 (57.03:1,153.74)** 1.72 (1.37:2.16)** 1.77 (0.36:8.66) NS
Cxcl2 33.43 ± 0.37 58.59 (38.10:90.12)*** 1.70 (1.17:2.46)* 2.60 (0.96:7.06) NS
Cxcl10 21.26 ± 0.41 38.52 (0.22:6,897.33) NS 0.79 (0.14:4.62) NS 1.30 (0.26:6.37) NS
Birc3 4.72 ± 0.26 6.72 (3.54:12.75)** 6.75 (0.25:2.25) NS 0.73 (0.23:2.30) NS
Esm1 6.21 ± 0.46 7.93 (2.42:25.96)* 0.78 (0.08:7.85) NS 0.78 (0.31:1.96) NS
Lcn2 3.15 ± 0.34 5.37 (1.41:20.45)* 0.52 (0.18:1.50) NS 0.83 (0.60:1.14) NS
NS not significant, CI confidence interval
Array data are those of Table 3 (Lcn2: P = 0.0102, rest: P B 0.001). PCR data: three pools of three animals each were compared to
same-sized control pools performing double measurements. *P B 0.05, **P B 0.01, ***P B 0.001
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promote the survival and differentiation of hippocampal
neurons [29, 30]. Ccl2 via its receptor CCR2 plays also an
important role in regulating the permeability of the blood–
brain-barrier which is reduced in CCR2(-/-) mice being
subjected to focal transient cerebral ischemia and which
was correlated with reduced infarct sizes [31]. However,
we did not find significant brain edema formation in our rat
model up to 4.5 h (unpublished data).
Since gene expression differences in the 1,400 W
group were only subtle as compared to controls in the
early phase of a sepsis syndrome significant immuno-
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Fig. 2 LPS-induced changes of mRNA expression in brain
homogenate and three compartments. Y-axis represent log fold
mRNA expressions of LPS-treated compared to NaCl-treated
animals after 4.5 h. Every spot represents a comparison of a NaCl
pool with an LPS pool (3 animals/pool). Horizontal lines indicate
the geometric mean. Chemokines and Esm1 were up-regulated,
especially within the hippocampus. *P B 0.05, **P B 0.01
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Therefore, our data support the notion of iNOS inhibitors
to be mainly vasoprotective agents improving the out-
come in a sepsis syndrome.
Norepinephrine seems to up-regulate the expression of
Ccl2, Ccl20, Cxcl1 and Cxcl2 (Table 5), what suggests a
possible proinflammatory potential of norepinephrine.
Recent experiments on endotoxin-induced lung inflam-
mation rendered a similar result, as phenylephrin
increased the formation of TNFa- and Cxcl2-specific
mRNA by lung neutrophils [32]. Other groups found that
norepinephrine exhibits proinflammatory properties onto
the systemic TNFa- and IL1b-release [33]. Tsuda et al.
[34] found an impairment of the host’s antibacterial
resistance by norepinephrine-activated neutrophils.
Additionally, the noradrenergic reuptake inhibitor desi-
pramine augments the stress-induced IL1b-response in
the hippocampus [35]. Nevertheless, the norepinephrine
therapy is still regarded as the most effective agent in
treating sepsis-related hypodynamic failure.
Neither 1,400 W nor norepinephrine had a significant
effect on the gene expression of Birc3 and Esm1, which
were both induced by LPS (Table 3, 5). Birc3 is neces-
sary for the maintenance of a normal, infection-triggered
innate immune response. Birc3-/- mice exhibit profound
resistance to LPS-induced sepsis, specifically because of
an attenuated inflammatory response [36]. Esm1 is a
novel endothelial cell dysfunction marker. Septic rats
showed an elevated Esm1 plasma level 4 h after LPS
administration [37]. In septic patients the Esm1 blood
level is related to the severity of illness and the outcome
of the patient [38]. Therefore we suspect that Esm1 and
Birc3 are two important genes that could be used as
markers in therapeutic sepsis approaches. Interestingly,
Esm1-specific mRNA was most intensively up-regulated
in the LPS-stimulated hippocampus (Fig. 2), what fore-
bodes a stronger susceptibility of hippocampal
capillaries.
Comparing the chemokine (Ccl2, Ccl20, Cxcl2)
expression levels of brain homogenate to those of the
hippocampus, the somatosensory cortex and the cerebel-
lum, we found a stronger LPS-effect in the selected
compartments (Fig. 2), in which the hippocampus
appeared to be most intensively stimulated. Consistent
with our findings it appears that the hippocampus is a
highly vulnerable brain region during experimental sepsis
[39]. These data are in line with the clinical observation
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Fig. 3 Cxcl1 and Cxcl2 protein expression in brain homogenate.
The LPS-induced up-regulation of mRNA could be validated on the
protein level (4.5 h after LPS/NaCl)
Fig. 4 Localization of target
genes. In immunofluorescence
staining of LPS-treated brains,
Cxcl1 accumulated in
hippocampal neurons as proved
by the neuron marker NeuN.
Cxcl2 was primarily located
within the axones of the white
matter. Neu/Cxcl1 9100, Cxcl2
9200; blue DAPI, red target
proteins
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However, a limitation of the technique is that brain
homogenate studies were not able to differentiate between
glial cells and neurons. According to our own experience,
laser-microdissection techniques were not suitable
because of the complex shape of neurons and glial cells
preventing isolation free of contaminations due to inter-
fering cell processes. Comparing different brain
compartments, the strong differences in gene expression
underline the role of neurons and glial cells and cannot be
related to blood vessel or blood cell effects. Accordingly,
immunofluorescence staining of Cxcl1 presented a similar
picture as NeuN with an accumulation in hippocampal
neurons (Fig. 4). Cxcl2 showed an accumulation within
the axones of the white matter.
The comparatively strong chemokine induction in the
hippocampus and to a lower degree in the somatosensory
cortex and the cerebellum could be explained by a pro-
nounced breakdown of the blood–brain-barrier in these
compartments, a stronger activation of astrocytes and an
increased production within resident neurons. As the
hippocampus seems to be the most susceptible region,
further therapeutic approaches should include this
compartment.
Conclusions
After LPS application, Esm1, Ccl2, Ccl20 and Cxcl2 were
found to be most intensively up-regulated within the
hippocampus. Hence, we assume that in sepsis-associated
delirium the hippocampus is a compartment with high
vulnerability. This is in line with the clinical observation
of confusion and disturbance of memory. Birc3 and Esm1
may be used as prognostic parameters in further thera-
peutic approaches. Norepinephrine and 1,400 W seem to
have no significant beneficial effect onto mRNA expres-
sion. Therefore, our data proved for the first time the
assumption of a mainly vasoprotective mechanism of
iNOS inhibitors in a sepsis syndrome.
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